David R. Langley

8.5k citations

82 papers · 5.6k indexed · 2 hit papers · h-index 35

Impact in

Virology top 1%
- HIV Research and Treatment
Hepatology top 1%
- Hepatitis C virus research

Papers in

Virology 13
- HIV Research and Treatment 13
Infectious Diseases 19
- HIV/AIDS drug development and treatment 18

Co-authors: Miklós Békés Craig M. Crews Nicholas A. Meanwell Richard J. Colonno Laurence H. Hurley Haiyong Han David E. Thurston Anupama Rangan
Journals: Bioorganic & Medicinal Chemistry Letters (15 papers)Journal of Medicinal Chemistry (6 papers)Journal of the American Chemical Society (6 papers)Journal of Virology (4 papers)Tetrahedron Letters (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

David R. Langley

81 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

PROTAC targeted protein degraders: the past is prologue 2022 · 1.9k citations

Peers

Countries citing papers authored by David R. Langley

Since Specialization

Citations

This map shows the geographic impact of David R. Langley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Langley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Langley more than expected).

Fields of papers citing papers by David R. Langley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Langley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Langley. The network helps show where David R. Langley may publish in the future.

Co-authors

The 25 scholars most cited alongside David R. Langley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David R. Langley Line = papers co-authored together David R. Langley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Accurate Physics-Based Prediction of Binding Affinities of RNA- and DNA-Targeting Ligands Journal of Chemical Information and Modeling ·Ara M. Abramyan, Anna Bochicchio, Chuanjie Wu, Wolfgang Damm, David R. Langley, Devleena Shivakumar, Dmitry Lupyan, Lingle Wang, Edward Harder, E.O. Oloo	2025	1
2	Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules Nature Structural & Molecular Biology ·Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter C. Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela Cacace, David R. Langley, Miklós Békés	2024	29
3	Design for Solubility May Reveal Induction of Amide Hydrogen/Deuterium Exchange by Protein Self-Association Journal of Molecular Biology ·Kyle Trainor, Colleen Doyle, Avril Metcalfe‐Roach, Julia Steckner, Daša Lipovšek, Heather Malakian, David R. Langley, Stanley R. Krystek, Elizabeth M. Meiering	2021	1
4	Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors Bioorganic & Medicinal Chemistry Letters ·Kevin M. Peese, B. Narasimhulu Naidu, Manoj Patel, Chen Li, David R. Langley, Brian Terry, Tricia Protack, Volodymyr Gali, Zeyu Lin, Himadri Samanta, Ming Zheng, Susan Jenkins, Ira B. Dicker, Mark Krystal, Nicholas A. Meanwell, Michael Walker	2019	6
5	A General Amino Acid Synthesis Enabled by Innate Radical Cross‐Coupling Angewandte Chemie International Edition ·Shengyang Ni, Alberto F. Garrido‐Castro, Rohan R. Merchant, Justine N. de Gruyter, Daniel C. Schmitt, James J. Mousseau, Gary M. Gallego, Shouliang Yang, Michael R. Collins, Jennifer X. Qiao, Kap‐Sun Yeung, David R. Langley, Michael A. Poss, Paul M. Scola, Tian Qin, Phil S. Baran	2018	116
6	A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site Molecular Pharmacology ·Ramkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, Mian Gao, Simon Low, Lisa Megson, David Wensel, Rick L. Pieschl, Debra J. Post-Munson, John B. Watson, David R. Langley, Michael K. Ahlijanian, Linda J. Bristow, James Herrington	2017	11
7	Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core Bioorganic & Medicinal Chemistry Letters ·Prasanna Sivaprakasam, Xiaojun Han, Rita L. Civiello, Swanee Jacutin-Porte, Kevin Kish, Matt Pokross, H.A. Lewis, Nazia Ahmed, Nicolas Szapiel, John A. Newitt, Eric T. Baldwin, Hong Xiao, Carol Krause, Hyunsoo Park, Michelle Nophsker, Jonathan Lippy, Catherine R. Burton, David R. Langley, John E. Macor, Gene M. Dubowchik	2015	100
8	Characterizations of HCV NS5A replication complex inhibitors Virology ·Donald R. O’Boyle, Jin-Hua Sun, Peter T. Nower, Julie A. Lemm, Robert A. Fridell, Chunfu Wang, J. Romine, Makonen Belema, Van N. Nguyen, Denis R. St. Laurent, Michael H. Serrano‐Wu, Lawrence B. Snyder, Nicholas A. Meanwell, David R. Langley, Min Gao	2013	35
9	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068 Journal of Antimicrobial Chemotherapy ·Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Neelanjana Ray, B. Eggers, Hua Fang, Fan Li, Matthew D. Healy, David R. Langley, Carey Hwang, Max Lataillade, George J. Hanna, Mark Krystal	2013	55
10	2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924 Bioorganic & Medicinal Chemistry Letters ·Mark G. Saulnier, David B. Frennesson, Mark D. Wittman, Kurt Zimmermann, Upender Velaparthi, David R. Langley, Charles Struzynski, Xiaopeng Sang, Joan M. Carboni, Aixin Li, Ann Greer, Zheng Yang, Praveen Balimane, Marco M. Gottardis, Ricardo M. Attar, Dolatrai M. Vyas	2008	20
11	Application of Standard Project Management Tools to Research--A Case Study from a Multi-National Clinical Trial. P. Gist, David R. Langley	2007	9
12	Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Harold Mastalerz, Ming Chang, Ashvinikumar V. Gavai, Walter L. Johnson, David R. Langley, Francis Y. Lee, Punit Marathe, Arvind Mathur, Simone Oppenheimer, James Tarrant, John S. Tokarski, Gregory D. Vite, Dolatrai M. Vyas, Henry Ν. C. Wong, Tai W. Wong, Hongjian Zhang, Guifen Zhang	2007	24
13	Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity Bioorganic & Medicinal Chemistry Letters ·Xiangdong Alan Wang, Christopher Cianci, Kuo‐Long Yu, Keith D. Combrink, Jan Willem Thuring, Yi Zhang, Rita L. Civiello, Kathleen F. Kadow, Julia Roach, Zhufang Li, David R. Langley, Mark Krystal, Nicholas A. Meanwell	2007	22
14	Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands Bioorganic & Medicinal Chemistry Letters ·Richard A. Hartz, Argyrios G. Arvanitis, Charles R. Arnold, Joseph P. Rescinito, Kimberly L. Hung, Ge Zhang, Harvey Wong, David R. Langley, Paul J. Gilligan, George L. Trainor	2005	57
15	Electrostatic interaction of π-Acidic amides with hydrogen-Bond acceptors Bioorganic & Medicinal Chemistry Letters ·Yi Li, Lawrence B. Snyder, David R. Langley	2003	15
16	The Vancomycin biosynthetic pathway is induced in oxygen-limited Amycolatopsis orientalis (ATCC 19795) cultures that do not produce antibiotic Enzyme and Microbial Technology ·Graeme A. Dunstan, Claudio Avignone–Rossa, David R. Langley, Michael E. Bushell	2000	12
17	Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity Bioorganic & Medicinal Chemistry Letters ·Paul Stead, Stephen Hiscox, Phil Robinson, Nicholas B. Pike, Philip J. Sidebottom, Andrew D. Roberts, NICHOLAS L. TAYLOR, Amy E. Wright, Shirley A. Pomponi, David R. Langley	2000	36
18	Molecular Dynamic Simulations of Environment and Sequence Dependent DNA Conformations: The Development of the BMS Nucleic Acid Force Field and Comparison with Experimental Results Journal of Biomolecular Structure and Dynamics ·David R. Langley	1998	97
19	Localisation of luciferase in luminous marine bacteria by gold immunocytochemical labelling FEMS Microbiology Letters ·Peter Angell, David R. Langley, A. H. L. Chamberlain	1989	5
20	E-ring desoxy analogs of etoposide Journal of Medicinal Chemistry ·Mark G. Saulnier, Dolatrai M. Vyas, David R. Langley, Terrence W. Doyle, William C. Rose, Alfred R. Crosswell, Byron H. Long	1989	26

About David R. Langley

David R. Langley is a scholar working on Virology, Infectious Diseases, Toxicology, Hepatology and Organic Chemistry, having authored 82 papers that have together received 5.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (13 papers), Protein Structure and Dynamics (9 papers), Biochemical and Molecular Research (9 papers), Cancer therapeutics and mechanisms (7 papers), Chemical Synthesis and Analysis (6 papers), Hepatitis C virus research (6 papers) and Synthetic Organic Chemistry Methods (5 papers). The work is most often cited by research in Virology (557 citations), Hepatology (908 citations), Infectious Diseases (919 citations), Organic Chemistry (1.3k citations) and Molecular Biology (3.1k citations). David R. Langley has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Miklós Békés, Craig M. Crews, Nicholas A. Meanwell, Richard J. Colonno, Laurence H. Hurley, Haiyong Han, David E. Thurston, Anupama Rangan, Dennis M. Grasela and John F. Kadow. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Journal of the American Chemical Society, Journal of Virology and Tetrahedron Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact